Structural maturation of HIV-1 reverse transcriptase—a metamorphic solution to genomic instability

Viruses

Volumn 8, Issue 10, 2016, Pages

  London, Robert E ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

HIV 1 reverse transcriptase; Metamorphic protein; Reverse transcriptase maturation pathway; RNase H domain; Structural heterodimer; Subunit specific RNase H domain unfolding

Indexed keywords

HETERODIMER; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEIN P66; PROTEIN PRECURSOR; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DIMERIZATION; GENE EXPRESSION REGULATION; GENE MUTATION; GENOMIC INSTABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN UNFOLDING; REVIEW; STRUCTURAL PROTEOMICS; VIRION;

EID: 84989291173     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v8100260     Document Type: Review

References (144)

1. Lindahl, T. Instability and decay of the primary structure of DNA. Nature 1993, 362, 709–715. [CrossRef] [PubMed]
2. Holmes, E.C. Error thresholds and the constraints to RNA virus evolution. Trends Microbiol. 2003, 11, 543–546. [CrossRef] [PubMed]
3. Smith, R.A.; Loeb, L.A.; Preston, B.D. Lethal mutagenesis of HIV. Virus Res. 2005, 107, 215–228. [CrossRef] [PubMed]
4. Roberts, J.D.; Bebenek, K.; Kunkel, T.A. The Accuracy of Reverse-Transcriptase from Hiv-1. Science 1988, 242, 1171–1173. [CrossRef] [PubMed]
5. Sierra, S.; Kupfer, B.; Kaiser, R. Basics of the virology of HIV-1 and its replication. J. Clin. Virol. 2005, 34, 233–244. [CrossRef] [PubMed]
6. Belshaw, R.; Pybus, O.G.; Rambaut, A. The evolution of genome compression and genomic novelty in RNA viruses. Genome Res. 2007, 17, 1496–1504. [CrossRef] [PubMed]
7. Biswas, P.; Jiang, X.; Pacchia, A.L.; Dougherty, J.P.; Peltz, S.W. The human immunodeficiency virus type 1 ribosomal frameshifting site is an invariant sequence determinant and an important target for antiviral therapy. J. Virol. 2004, 78, 2082–2087. [CrossRef] [PubMed]
8. Jacks, T.; Power, M.D.; Masiarz, F.R.; Luciw, P.A.; Barr, P.J.; Varmus, H.E. Characterization of Ribosomal Frameshifting in Hiv-1 Gag-Pol Expression. Nature 1988, 331, 280–283. [CrossRef] [PubMed]
9. Mouzakis, K.D.; Lang, A.L.; Vander Meulen, K.A.; Easterday, P.D.; Butcher, S.E. HIV-1 frameshift efficiency is primarily determined by the stability of base pairs positioned at the mRNA entrance channel of the ribosome. Nucleic Acids Res. 2013, 41, 1901–1913. [CrossRef] [PubMed]
10. Geyer, M.; Fackler, O.T.; Peterlin, B.M. Structure-function relationships in HIV-1 Nef. EMBO Rep. 2001, 2, 580–585. [CrossRef] [PubMed]
11. Malim, M.H.; Emerman, M. HIV-1 accessory proteins—Ensuring viral survival in a hostile environment. Cell Host Microbe 2008, 3, 388–398. [CrossRef] [PubMed]
12. Schubert, U.; Bour, S.; Ferrer-Montiel, A.V.; Montal, M.; Maldarell, F.; Strebel, K. The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J. Virol. 1996, 70, 809–819. [PubMed]
13. Katz, R.A.; Skalka, A.M. The Retroviral Enzymes. Annu. Rev. Biochem. 1994, 63, 133–173. [CrossRef] [PubMed]
14. Wlodawer, A.; Miller, M.; Jaskólski, M.; Sathyanarayana, B.K.; Baldwin, E.; Weber, I.T.; Selk, L.M.; Clawson, L.; Schneider, J.; Kent, S.B. Conserved Folding in Retroviral Proteases—Crystal-Structure of a Synthetic Hiv-1 Protease. Science 1989, 245, 616–621. [CrossRef] [PubMed]
15. Hare, S.; Gupta, S.S.; Valkov, E.; Engelman, A.; Cherepanov, P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010, 464, 232–237. [CrossRef] [PubMed]
16. Zheng, X.; Pedersen, L.C.; Gabel, S.A.; Mueller, G.A.; Cuneo, M.J.; DeRose, E.F.; Krahn, J.M.; London, R.E. Selective unfolding of one Ribonuclease H domain of HIV reverse transcriptase is linked to homodimer formation. Nucleic Acids Res. 2014, 42, 5361–5377. [CrossRef] [PubMed]
17. Jochmans, D. Novel HIV-1 reverse transcriptase inhibitors. Virus Res. 2008, 134, 171–185. [CrossRef] [PubMed]
18. Sarafianos, S.G.; Marchand, B.; Das, K.; Himmel, D.M.; Parniak, M.A.; Hughes, S.H.; Arnold, E. Structure and Function of HIV-1 Reverse Transcriptase: Molecular Mechanisms of Polymerization and Inhibition. J. Mol. Biol. 2009, 385, 693–713. [CrossRef] [PubMed]
19. Menendez-Arias, L. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res. 2008, 134, 124–146. [CrossRef] [PubMed]
20. Lewis, W.; Day, B.J.; Copeland, W.C. Mitochondrial toxicity of NRTI antiviral drugs: An integrated cellular perspective. Nat. Rev. Drug Discov. 2003, 2, 812–822. [CrossRef] [PubMed]
21. Ding, J.; Jacobo-Molina, A.; Tantillo, C.; Lu, X.; Nanni, R.G.; Arnold, E. Buried surface analysis of HIV-1 reverse transcriptase p66/p51 heterodimer and its interaction with dsDNA template/primer. J. Mol. Recognit. 1994, 7, 157–161. [CrossRef] [PubMed]
22. Kohlstaedt, L.A.; Wang, J.; Friedman, J.M.; Rice, P.A.; Steitz, T.A. Crystal-Structure at 3.5 Angstrom Resolution of Hiv-1 Reverse-Transcriptase Complexed with an Inhibitor. Science 1992, 256, 1783–1790. [CrossRef] [PubMed]
23. Davies, J.F.; Hostomska, Z.; Hostomsky, Z.; Jordan, S.R.; Matthews, D.A. Crystal-Structure of the Ribonuclease-H Domain of Hiv-1 Reverse-Transcriptase. Science 1991, 252, 88–95. [CrossRef] [PubMed]
24. Zheng, X.; Perera, L.; Mueller, G.A.; DeRose, E.F.; London, R.E. Asymmetric conformational maturation of HIV-1 reverse transcriptase. eLife 2015, 4, e06359.
25. Zheng, X.H.; Mueller, G.A.; Cuneo, M.J.; DeRose, E.F.; London, R.E. Homodimerization of the p51 Subunit of HIV-1 Reverse Transcriptase. Biochemistry 2010, 49, 2821–2833. [CrossRef] [PubMed]
26. Kensch, O.; Restle, T.; WoÈhrl, B.M.; Goody, R.S.; Steinhoff, H.J. Temperature-dependent equilibrium between the open and closed conformation of the p66 subunit of HIV-1 reverse transcriptase revealed by site-directed spin labelling. J. Mol. Biol. 2000, 301, 1029–1039. [CrossRef] [PubMed]
27. Hsiou, Y.; Ding, J.; Das, K.; Clark, A.D.; Hughes, S.H.; Arnold, E. Structure of unliganded HIV-1 reverse transcriptase at 2.7 angstrom resolution: Implications of conformational changes for polymerization and inhibition mechanisms. Structure 1996, 4, 853–860. [CrossRef]
28. Das, K.; Clark, A.D.; Lewi, P.J.; Heeres, J.; de Jonge, M.R.; Koymans, L.M.H.; Vinkers, H.M.; Daeyaert, F.; Ludovici, D.W.; Kukla, M.J.; et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 2004, 47, 2550–2560. [PubMed]
29. Unge, T.; Knight, S.; Bhikhabhai, R.; Lovgren, S.; Dauter, Z.; Wilson, K.; Strandberg, B. 2.2 A resolution structure of the amino-terminal half of HIV-1 reverse transcriptase (fingers and palm subdomains). Structure 1994, 2, 953–961. [CrossRef]
30. Himmel, D.M.; Maegley, K.A.; Pauly, T.A.; Bauman, J.D.; Das, K.; Dharia, C.; Clark, A.D.; Ryan, K.; Hickey, M.J.; Love, R.A.; et al. Structure of HIV-1 Reverse Transcriptase with the Inhibitor beta-Thujaplicinol Bound at the RNase H Active Site. Structure 2009, 17, 1625–1635. [CrossRef] [PubMed]
31. Zheng, X.; Pedersen, L.C.; Gabel, S.A.; Mueller, G.A.; DeRose, E.F.; London, R.E. Unfolding the HIV-1 reverse transcriptase RNase H domain - how to lose a molecular tug-of-war. Nucleic Acids Res. 2016, 44, 1776–1788. [CrossRef] [PubMed]
32. Ren, J.; Milton, J.; Weaver, K.L.; Short, S.A.; Stuart, D.I.; Stammers, D.K. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure 2000, 8, 1089–1094. [CrossRef]
33. Esnouf, R.; Ren, J.S.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. Mechanism of Inhibition of Hiv-1 Reverse-Transcriptase by Nonnucleoside Inhibitors. Nat. Struct. Biol. 1995, 2, 303–308. [CrossRef] [PubMed]
34. Ren, J.; Bird, L.E.; Chamberlain, P.P.; Stewart-Jones, G.B.; Stuart, D.I.; Stammers, D.K. Structure of HIV-2 reverse transcriptase at 2.35-angstrom resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc. Natl. Acad. Sci. USA 2002, 99, 14410–14415. [CrossRef] [PubMed]
35. Schulze, T.; Nawrath, M.; Moelling, K. Cleavage of the Hiv-1 P66 Reverse-Transcriptase Rnase-H by the P9 Protease in vitro Generates Active P15 Rnase-H. Arch. Virol. 1991, 118, 179–188. [CrossRef] [PubMed]
36. Tomasselli, A.G.; Sarcich, J.L.; Barrett, L.J.; Reardon, I.M.; Howe, W.J.; Evans, D.B.; Sharma, S.K.; Heinrikson, R.L. Human-Immunodeficiency-Virus Type-1 Reverse-Transcriptase and Ribonuclease-H as Substrates of the Viral Protease. Protein Sci. 1993, 2, 2167–2176. [CrossRef] [PubMed]
37. Chattopadhyay, D.; Evans, D.B.; Deibel, M.R., Jr.; Vosters, A.F.; Eckenrode, F.M.; Einspahr, H.M.; Hui, J.O.; Tomasselli, A.G.; Zurcher-Neely, H.A.; Heinrikson, R.L. Purification and Characterization of Heterodimeric Human-Immunodeficiency-Virus Type-1 (Hiv-1) Reverse-Transcriptase Produced by in vitro Processing of P66 with Recombinant Hiv-1 Protease. J. Biol. Chem. 1992, 267, 14227–14232. [PubMed]
38. Slack, R.L.; Spiriti, J.; Ahn, J.; Parniak, M.A.; Zuckerman, D.M.; Ishima, R. Structural integrity of the ribonuclease H domain in HIV-1 reverse transcriptase. Proteins-Struct. Funct. Bioinform. 2015, 83, 1526–1538. [CrossRef] [PubMed]
39. Navarro, J.M.; Damier, L.; Boretto, J.; Priet, S.; Canard, B.; Quérat, G.; Sire, J. Glutamic residue 438 within the protease-sensitive subdomain of HIV-1 reverse transcriptase is critical for heterodimer processing in viral particles. Virology 2001, 290, 300–308. [CrossRef] [PubMed]
40. Wapling, J.; Moore, K.L.; Sonza, S.; Mak, J.; Tachedjian, G. Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer. J. Virol. 2005, 79, 10247–10257. [CrossRef] [PubMed]
41. Sluis-Cremer, N.; Arion, D.; Abram, M.E.; Parniak, M.A. Proteolytic processing of an HIV-1 pol polyprotein precursor: Insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation. Int. J. Biochem. Cell Biol. 2004, 36, 1836–1847. [CrossRef] [PubMed]
42. Murzin, A.G. Biochemistry—Metamorphic proteins. Science 2008, 320, 1725–1726. [CrossRef] [PubMed]
43. Bryan, P.N.; Orban, J. Proteins that switch folds. Curr. Opin. Struct. Biol. 2010, 20, 482–488. [CrossRef] [PubMed]
44. Doublie, S.; Sawaya, M.R.; Ellenberger, T. An open and closed case for all polymerases. Struct Fold. Des. 1999, 7, R31–R35. [CrossRef]
45. Sawaya, M.R.; Pelletier, H.; Kumar, A.; Wilson, S.H.; Kraut, J. Crystal-Structure of Rat DNA-Polymerase-Beta— Evidence for a Common Polymerase Mechanism. Science 1994, 264, 1930–1935. [CrossRef] [PubMed]
46. Wong, J.H.; Fiala, K.A.; Suo, Z.; Ling, H. Snapshots of a Y-family DNA polymerase in replication: Substrate-induced conformational transitions and implications for fidelity of Dpo 4. J. Mol. Biol. 2008, 379, 317–330. [CrossRef] [PubMed]
47. Lansdon, E.B.; Samuel, D.; Lagpacan, L.; Brendza, K.M.; White, K.L.; Hung, M.; Ray, A.S. Visualizing the Molecular Interactions of a Nucleotide Analog, GS-9148, with HIV-1 Reverse Transcriptase-DNA Complex. J. Mol. Biol. 2010, 397, 967–978. [CrossRef] [PubMed]
48. Wang, J.; Smerdon, S.J.; Jäger, J.; Kohlstaedt, L.A.; Rice, P.A.; Friedman, J.M.; Steitz, T.A. Structural Basis of Asymmetry in the Human-Immunodeficiency-Virus Type-1 Reverse-Transcriptase Heterodimer. Proc. Natl. Acad. Sci. USA 1994, 91, 7242–7246. [CrossRef] [PubMed]
49. Cabodevilla, J.F.; Odriozola, L.; Santiago, E.; Martínez-Irujo, J.J. Factors affecting the dimerization of the p66 form of HIV-1 reverse transcriptase. Eur. J. Biochem. 2001, 268, 1163–1172. [CrossRef] [PubMed]
50. Venezia, C.F.; Howard, K.J.; Ignatov, M.E.; Holladay, L.A.; Barkley, M.D. Effects of efavirenz binding on the subunit equilibria of HIV-1 reverse transcriptase. Biochemistry 2006, 45, 2779–2789. [CrossRef] [PubMed]
51. Jacobo-Molina, A.; Arnold, E. Hiv Reverse-Transcriptase Structure-Function-Relationships. Biochemistry 1991, 30, 6351–6361. [CrossRef] [PubMed]
52. Ding, J.P.; Das, K.; Hsiou, Y.; Sarafianos, S.G.; Clark, A.D.; Jacobo-Molina, A.; Arnold, E. Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 angstrom resolution. J. Mol. Biol. 1998, 284, 1095–1111. [CrossRef] [PubMed]
53. Hostomska, Z.; Matthews, D.A.; Davies, J.F.; Nodes, B.R.; Hostomsky, Z. Proteolytic Release and Crystallization of the Rnase-H Domain of Human-Immunodeficiency-Virus Type-1 Reverse-Transcriptase. J. Biol. Chem. 1991, 266, 14697–14702. [PubMed]
54. Pattyn, E.; Lavens, D.; Van der Heyden, J.; Verhee, A.; Lievens, S.; Lemmens, I.; Tavernier, J. MAPPIT (MAmmalian Protein-Protein Interaction Trap) as a tool to study HIV reverse transcriptase dimerization in intact human cells. J. Virol. Meth. 2008, 153, 7–15. [CrossRef] [PubMed]
55. Divita, G.; Restle, T.; Goody, R.S. Characterization of the Dimerization Process of Hiv-1 Reverse-Transcriptase Heterodimer Using Intrinsic Protein Fluorescence. FEBS Lett. 1993, 324, 153–158. [CrossRef]
56. Venezia, C.F.; Meany, B.J.; Braz, V.A.; Barkley, M.D. Kinetics of Association and Dissociation of HIV-1 Reverse Transcriptase Subunits. Biochemistry 2009, 48, 9084–9093. [CrossRef] [PubMed]
57. Paris, K.A.; Haq, O.; Felts, A.K.; Das, K.; Arnold, E.; Levy, R.M. Conformational Landscape of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Non-Nucleoside Inhibitor Binding Pocket: Lessons for Inhibitor Design from a Cluster Analysis of Many Crystal Structures. J. Med. Chem. 2009, 52, 6413–6420. [CrossRef] [PubMed]
58. Tantillo, C.; Ding, J.; Jacobo-Molina, A.; Nanni, R.G.; Boyer, P.L.; Hughes, S.H.; Arnold, E. Locations of Anti-Aids Drug-Binding Sites and Resistance Mutations in the 3-Dimensional Structure of Hiv-1 Reverse-Transcriptase—Implications for Mechanisms of Drug-Inhibition and Resistance. J. Mol. Biol. 1994, 243, 369–387. [CrossRef] [PubMed]
59. Chou, P.Y.; Fasman, G.D. Prediction of Beta-Turns. Biophys. J. 1979, 26, 367–383. [CrossRef]
60. Goel, R.; Beard, W.A.; Kumar, A.; Casas-Finet, J.R.; Strub, M.P.; Stahl, S.J.; Becerra, S.P. Structure-Function Studies of Hiv-1(1) Reverse-Transcriptase—Dimerization-Defective Mutant L289k. Biochemistry 1993, 32, 13012–13018. [CrossRef] [PubMed]
61. Pandey, P.K.; Kaushik, N.; Singh, K.; Sharma, B.; Upadhyay, A.K.; Kumar, S.; Pandey, V.N. Insertion of a small peptide of six amino acids into the beta 7-beta 8 loop of the p51 subunit of HIV-1 reverse transcriptase perturbs the heterodimer and affects its activities. BMC Biochemistry 2002, 3, 18. [CrossRef] [PubMed]
62. Mulky, A.; Vu, B.C.; Conway, J.A.; Hughes, S.H.; Kappes, J.C. Analysis of amino acids in the beta 7-beta 8 loop of human immunodeficiency virus type 1 reverse transcriptase for their role in virus replication. J. Mol. Biol. 2007, 365, 1368–1378. [CrossRef] [PubMed]
63. Sharma, S.K.; Fan, N.S.; Evans, D.B. Human-Immunodeficiency-Virus Type-1 (Hiv-1) Recombinant Reverse-Transcriptase—Asymmetry in P66 Subunits of the P66/P66 Homodimer. FEBS Lett. 1994, 343, 125–130. [CrossRef]
64. Sharaf, N.G.; Poliner, E.; Slack, R.L.; Christen, M.T.; Byeon, I.J. L.; Parniak, M.A.; Ishima, R. The p66 immature precursor of HIV-1 reverse transcriptase. Proteins 2014, 82, 2343–2352. [CrossRef] [PubMed]
65. Santos, A.F.; Lengruber, R.B.; Soares, E.A.; Jere, A.; Sprinz, E.; Martinez, A.M.; Soares, M.A. Conservation patterns of HIV-1 RT connection and RNase H domains: Identification of new mutations in NRTI-treated patients. PLoS ONE 2008, 3, e1781. [CrossRef] [PubMed]
66. Kern, G.; Handel, T.; Marqusee, S. Characterization of a folding intermediate from HIV-1 ribonuclease H. Protein Sci. 1998, 7, 2164–2174. [CrossRef] [PubMed]
67. Byeon, I.J.; Louis, J.M.; Gronenborn, A.M. A captured folding intermediate involved in dimerization and domain-swapping of GB 1. J. Mol. Biol. 2004, 340, 615–625. [CrossRef] [PubMed]
68. Newcomer, M.E. Protein folding and three-dimensional domain swapping: A strained relationship? Curr. Opin. Struct. Biol. 2002, 12, 48–53. [CrossRef]
69. Rousseau, F.; Schymkowitz, J.; Itzhaki, L.S. Implications of 3D domain swapping for protein folding, misfolding and function. Adv. Exp. Med. Biol. 2012, 747, 137–152. [PubMed]
70. Rousseau, F.; Schymkowitz, J.W.; Itzhaki, L.S. The unfolding story of three-dimensional domain swapping. Structure 2003, 11, 243–251. [CrossRef]
71. Pari, K.; Mueller, G.A.; DeRose, E.F.; Kirby, T.W.; London, R.E. Solution structure of the RNase H domain of the HIV-1 reverse transcriptase in the presence of magnesium. Biochemistry 2003, 42, 639–650. [CrossRef] [PubMed]
72. Christen, M.T.; Menon, L.; Myshakina, N.S.; Ahn, J.; Parniak, M.A.; Ishima, R. Structural basis of the allosteric inhibitor interaction on the HIV-1 reverse transcriptase RNase H domain. Chem. Biol. Drug. Des. 2012, 80, 706–716. [CrossRef] [PubMed]
73. Divita, G.; Rittinger, K.; Geourjon, C.; Deléage, G.; Goody, R.S. Dimerization Kinetics of Hiv-1 and Hiv-2 Reverse-Transcriptase—A 2-Step Process. J. Mol. Biol. 1995, 245, 508–521. [CrossRef] [PubMed]
74. Rowley, G.L.; Ma, Q.F.; Bathurst, I.C.; Barr, P.J.; Kenyon, G.L. Stabilization and Activation of Recombinant Human Immunodeficiency Virus-1 Reverse Transcriptase-P 66. Biochem. Biophys. Res. Commun. 1990, 167, 673–679. [CrossRef]
75. Tachedjian, G.; Orlova, M.; Sarafianos, S.G.; Arnold, E.; Goff, S.P. Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc. Natl. Acad. Sci. USA 2001, 98, 7188–7193. [CrossRef] [PubMed]
76. Tachedjian, G.; Moore, K.L.; Goff, S.P.; Sluis-Cremer, N. Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation. FEBS Lett. 2005, 579, 379–384. [CrossRef] [PubMed]
77. Sluis-Cremer, N.; Arion, D.; Parniak, M.A. Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. Mol. Pharmacol. 2002, 62, 398–405. [CrossRef] [PubMed]
78. Camarasa, M.J.; Velazquez, S.; San-Felix, A.; Perez-Perez, M.J.; Bonache, M.C.; Castro, S.D. TSAO derivatives, inhibitors of HIV-1 reverse transcriptase dimerization: Recent progress. Curr. Pharm. Des. 2006, 12, 1895–1907. [CrossRef] [PubMed]
79. Sluis-Cremer, N.; Hamamouch, N.; San Félix, A.; Velazquez, S.; Balzarini, J.; Camarasa, M.J. Structure-activity relationships of [20,50-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-30-spiro-5”-(4”-amino-1”,2”- oxathiole-2”,2”-dioxide) thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization. J. Med. Chem. 2006, 49, 4834–4841. [CrossRef] [PubMed]
80. Das, K.; Martinez, S.E.; Bauman, J.D.; Arnold, E. HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism. Nat. Struct. Mol. Biol. 2012, 19, 253–259. [CrossRef] [PubMed]
81. Pandey, P.K.; Kaushik, N.; Talele, T.T.; Yadav, P.N.S.; Pandey, V.N. Insertion of a peptide from MuLV RT into the connection subdomain of HIV-1 RT results in a functionally active chimeric enzyme in monomeric conformation. Mol. Cell. Biochem. 2001, 225, 135–144. [CrossRef] [PubMed]
82. Tachedjian, G.; Radzio, J.; Sluis-Cremer, N. Relationship between enzyme activity and dimeric structure of recombinant HIV-1 reverse transcriptase. Proteins-Struct. Funct. Bioinform. 2005, 60, 5–13. [CrossRef] [PubMed]
83. Das, K.; Bauman, J.D.; Rim, A.S.; Dharia, C.; Clark, A.D., Jr.; Camarasa, M.J.; Arnold, E. Crystal Structure of tert-Butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in Complex with HIV-1 Reverse Transcriptase (RT) Redefines the Elastic Limits of the Non-nucleoside Inhibitor-Binding Pocket. J. Med. Chem. 2011, 54, 2727–2737. [CrossRef] [PubMed]
84. Sluis-Cremer, N.; Dmitrienko, G.I.; Balzarini, J.; Camarasa, M.J.; Parniak, M.A. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-{spiro[4”-amino-2”,2”-dioxo-1”,2”-oxathiole- 5”,30-[20,50-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]}-3-ethylthymine. Biochemistry 2000, 39, 1427–1433. [CrossRef] [PubMed]
85. Divita, G.; Restle, T.; Goody, R.S.; Chermann, J.C.; Baillon, J.G. Inhibition of Human-Immunodeficiency-Virus Type-1 Reverse-Transcriptase Dimerization Using Synthetic Peptides Derived from the Connection Domain. J. Biol. Chem. 1994, 269, 13080–13083. [PubMed]
86. Nissley, D.V.; Radzio, J.; Ambrose, Z.; Sheen, C.W.; Hamamouch, N.; Moore, K.L.; Sluis-Cremer, N. Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT. Biochem. J. 2007, 404, 151–157. [CrossRef] [PubMed]
87. Figueiredo, A.; Moore, K.L.; Mak, J.; Sluis-Cremer, N.; de Bethune, M.P.; Tachedjian, G. Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. PLoS Pathog. 2006, 2, 1051–1059. [CrossRef] [PubMed]
88. Das, K.; Sarafianos, S.G.; Clark, A.D.; Boyer, P.L.; Hughes, S.H.; Arnold, E. Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097. J. Mol. Biol. 2007, 365, 77–89. [CrossRef] [PubMed]
89. Huang, H.; Chopra, R.; Verdine, G.L.; Harrison, S.C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 1998, 282, 1669–1675. [CrossRef] [PubMed]
90. Zheng, X.H.; Mueller, G.A.; DeRose, E.F.; London, R.E. Protein-Mediated Antagonism between HIV Reverse Transcriptase Ligands Nevirapine and MgATP. Biophys. J. 2013, 104, 2695–2705. [CrossRef] [PubMed]
91. Figueiredo, A.; Zelina, S.; Sluis-Cremer, N.; Tachedjian, G. Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability. Curr. HIV Res. 2008, 6, 130–137. [CrossRef] [PubMed]
92. Tachedjian, G.; Aronson, H.E.G.; Goff, S.P. Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptase. Proc. Natl. Acad. Sci. USA 2000, 97, 6334–6339. [CrossRef] [PubMed]
93. Ghosh, M.; Jacques, P.S.; Rodgers, D.W.; Ottman, M.; Darlix, J.L.; Le Grice, S.F. Alterations to the primer grip of p66 HIV-1 reverse transcriptase and their consequences for template-primer utilization. Biochemistry 1996, 35, 8553–8562. [CrossRef] [PubMed]
94. Wohrl, B.M.; Krebs, R.; Thrall, S.H.; Le Grice, S.F.; Scheidig, A.J.; Goody, R.S. Kinetic analysis of four HIV-1 reverse transcriptase enzymes mutated in the primer grip region of p66—Implications for DNA synthesis and dimerization. J. Biol. Chem. 1997, 272, 17581–17587. [CrossRef] [PubMed]
95. Mulky, A.; Sarafianos, S.G.; Jia, Y.; Arnold, E.; Kappes, J.C. Identification of amino acid residues in the human immunodeficiency virus type-1 reverse transcriptase tryptophan-repeat motif that are required for subunit interaction using infectious virions. J. Mol. Biol. 2005, 349, 673–684. [CrossRef] [PubMed]
96. Tachedjian, G.; Aronson, H.E.G.; de los Santos, M.; Seehra, J.; McCoy, J.M.; Goff, S.P. Role of residues in the tryptophan repeat motif for HIV-1 reverse transcriptase dimerization. J. Mol. Biol. 2003, 326, 381–396. [CrossRef]
97. Auwerx, J.; Van Nieuwenhove, J.; Rodríguez-Barrios, F.; de Castro, S.; Velázquez, S.; Ceccherini-Silberstein, F.; Balzarini, J. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type I (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs. FEBS Lett. 2005, 579, 2294–2300. [CrossRef] [PubMed]
98. Malkov, S.N.; Živković, M.V.; Beljanski, M.V.; Hall, M.B.; Zarić, S.D. A reexamination of the propensities of amino acids towards a particular secondary structure: Classification of amino acids based on their chemical structure. J. Mol. Model. 2008, 14, 769–775. [CrossRef] [PubMed]
99. Ceccherini-Silberstein, F.; Gago, F.; Santoro, M.; Gori, C.; Svicher, V.; Rodríguez-Barrios, F.; Balzarini, J. High sequence conservation of human immunodeficiency virus-type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations. J. Virol. 2005, 79, 10718–10729. [CrossRef] [PubMed]
100. Fujiwara, T.; Sato, A.; El-Farrash, M.; Miki, S.; Abe, K.; Isaka, Y.; Sugimoto, H. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 1998, 42, 1340–1345. [PubMed]
101. Feng, M.Z.; Wang, D.; Grobler, J.A.; Hazuda, D.J.; Miller, M.D.; Lai, M.T. In Vitro Resistance Selection with Doravirine (MK-1439), a Novel Nonnucleoside Reverse Transcriptase Inhibitor with Distinct Mutation Development Pathways. Antimicrob. Agents Chemother. 2015, 59, 590–598. [CrossRef] [PubMed]
102. Sato, A.; Hammond, J.; Alexander, T.N.; Graham, J.P.; Binford, S.; Sugita, K.I.; Patick, A.K. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor. Antivir. Res. 2006, 70, 66–74. [CrossRef] [PubMed]
103. Lu, M.Q.; Felock, P.J.; Munshi, V.; Hrin, R.C.; Wang, Y.J.; Yan, Y.; Williams, T.M. Antiviral Activity and In Vitro Mutation Development Pathways of MK-6186, a Novel Nonnucleoside Reverse Transcriptase Inhibitor. Antimicrob. Agents Chemother. 2012, 56, 3324–3335. [CrossRef] [PubMed]
104. Willard, L.; Ranjan, A.; Zhang, H.; Monzavi, H.; Boyko, R.F.; Sykes, B.D.; Wishart, D.S. VADAR: A web server for quantitative evaluation of protein structure quality. Nucleic Acids Res. 2003, 31, 3316–3319. [CrossRef] [PubMed]
105. Mulky, A.; Sarafianos, S.G.; Arnold, E.; Wu, X.; Kappes, J.C. Subunit-specific analysis of the human immunodeficiency virus type 1 reverse transcriptase in vivo. J. Virol. 2004, 78, 7089–7096. [CrossRef] [PubMed]
106. Bacheler, L.; Jeffrey, S.; Hanna, G.; D’Aquila, R.; Wallace, L.; Logue, K.; Baker, D. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol. 2001, 75, 4999–5008. [CrossRef] [PubMed]
107. Kleim, J.P.; Bender, R.; Kirsch, R.; Meichsner, C.; Paessens, A.; Rösner, M.; Schneweis, K.E. Preclinical Evaluation of Hby-097, a New Nonnucleoside Reverse-Transcriptase Inhibitor of Human-Immunodeficiency-Virus Type-1 Replication. Antimicrob. Agents Chemother. 1995, 39, 2253–2257. [CrossRef] [PubMed]
108. Kolomeets, A.N.; Varghese, V.; Lemey, P.; Bobkova, M.R.; Shafer, R.W. A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. AIDS 2014, 28, F1–F8. [CrossRef] [PubMed]
109. Neogi, U.; Anita, S.H.E.T.; Shamsundar, R.; Ekstrand, M.L. Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: Evidence of etravirine cross-resistance. AIDS 2011, 25, 1123–1126. [CrossRef] [PubMed]
110. Paolucci, S.; Baldanti, F.; Campanini, G.; Cancio, R.; Belfiore, A.; Maga, G.; Gerna, G. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine. Antivir. Res. 2007, 76, 99–103. [CrossRef] [PubMed]
111. Wang, J.; Dykes, C.; Domaoal, R.A.; Koval, C.E.; Bambara, R.A.; Demeter, L.M. The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys,3) that correlate with reductions in replication efficiency. Virology 2006, 348, 462–474. [PubMed]
112. Abram, M.E.; Parniak, M.A. Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain. J. Virol. 2005, 79, 11952–11961. [CrossRef] [PubMed]
113. Abram, M.E.; Sarafianos, S.G.; Parniak, M.A. The mutation T477A in HIV-1 reverse transcriptase (RT) restores normal proteolytic processing of RT in virus with Gag-Pol mutated in the p51-RNH cleavage site. Retrovirology 2010, 7, 6. [CrossRef] [PubMed]
114. Chou, P.Y.; Fasman, G.D. Empirical Predictions of Protein Conformation. Annu. Rev. Biochem. 1978, 47, 251–276. [CrossRef] [PubMed]
115. Deshmukh, L.; Ghirlando, R.; Clore, G.M. Conformation and dynamics of the Gag polyprotein of the human immunodeficiency virus 1 studied by NMR spectroscopy. Proc. Natl. Acad. Sci. USA 2015, 112, 3374–3379. [CrossRef] [PubMed]
116. Li, H.; Dou, J.; Ding, L.; Spearman, P. Myristoylation is required for human immunodeficiency virus type 1 gag-gag multimerization in mammalian cells. J. Virol. 2007, 81, 12899–12910. [CrossRef] [PubMed]
117. Sudo, S.; Haraguchi, H.; Hirai, Y.; Gatanaga, H.; Sakuragi, J.I.; Momose, F.; Morikawa, Y. Efavirenz Enhances HIV-1 Gag Processing at the Plasma Membrane through Gag-Pol Dimerization. J. Virol. 2013, 87, 3348–3360. [CrossRef] [PubMed]
118. Konnyu, B.; Sadiq, S.K.; Turányi, T.; Hírmondó, R.; Müller, B.; Kräusslich, H.G.; Müller, V. Gag-Pol Processing during HIV-1 Virion Maturation: A Systems Biology Approach. PLoS Comput. Biol. 2013, 9, e1003103. [CrossRef] [PubMed]
119. Zheng, X.; Mueller, G.A.; DeRose, E.F.; London, R.E. Metal and ligand binding to the HIV-RNase H active site are remotely monitored by Ile 556. Nucleic Acids Res. 2012, 40, 10543–10553. [CrossRef] [PubMed]
120. Powers, R.; Clore, G.M.; Stahl, S.J.; Wingfield, P.T.; Gronenborn, A. Analysis of the Backbone Dynamics of the Ribonuclease-H Domain of the Human-Immunodeficiency-Virus Reverse-Transcriptase Using N-15-Relaxation Measurements. Biochemistry 1992, 31, 9150–9157. [CrossRef] [PubMed]
121. Mueller, G.A.; Pari, K.; DeRose, E.F.; Kirby, T.W.; London, R.E. Backbone dynamics of the RNase H domain of HIV-1 reverse transcriptase. Biochemistry 2004, 43, 9332–9342. [CrossRef] [PubMed]
122. Pettit, S.C.; Lindquist, J.N.; Kaplan, A.H.; Swanstrom, R. Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology 2005, 2, 66. [CrossRef] [PubMed]
123. Louis, J.M.; Clore, G.M.; Gronenborn, A.M. Autoprocessing of HIV-1 protease is tightly coupled to protein folding. Nat. Struct. Biol. 1999, 6, 868–875. [PubMed]
124. Agosto, L.M.; Zhong, P.; Munro, J.; Mothes, W. Highly Active Antiretroviral Therapies Are Effective against HIV-1 Cell-to-Cell Transmission. PLoS Pathog. 2014, 10, e1003982. [CrossRef] [PubMed]
125. Warrilow, D.; Stenzel, D.; Harrich, D. Isolated HIV-1 core is active for reverse transcription. Retrovirology 2007, 4, 77. [CrossRef] [PubMed]
126. Kleiman, L.; Jones, C.P.; Musier-Forsyth, K. Formation of the tRNALys packaging complex in HIV-1. FEBS Lett. 2010, 584, 359–365. [CrossRef] [PubMed]
127. Lapadat-Tapolsky, M.; Pernelle, C.; Borie, C.; Darlix, J.L. Analysis of the nucleic acid annealing activities of nucleocapsid protein from HIV-1. Nucleic Acids Res. 1995, 23, 2434–2441. [CrossRef] [PubMed]
128. Thomas, J.A.; Gorelick, R.J. Nucleocapsid protein function in early infection processes. Virus Res. 2008, 134, 39–63. [CrossRef] [PubMed]
129. Druillennec, S.; Caneparo, A.; de Rocquigny, H.; Roques, B.P. Evidence of interactions between the nucleocapsid protein NCp7 and the reverse transcriptase of HIV-1. J. Biol. Chem. 1999, 274, 11283–11288. [CrossRef] [PubMed]
130. Delviks-Frankenberry, K.A.; Nikolenko, G.N.; Barr, R.; Pathak, V.K. Mutations in human immunodeficiency virus type 1 RNaseHprimer grip enhance 3-Azido-3’-deoxythymidine resistance. J. Virol. 2007, 81, 6837–6845. [CrossRef] [PubMed]
131. Sarafianos, S.G.; Das, K.; Tantillo, C.; Clark, A.D.; Ding, J.; Whitcomb, J.M.; Arnold, E. Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA: DNA. EMBO J. 2001, 20, 1449–1461. [CrossRef] [PubMed]
132. Padilla-Parra, S.; Marin, M.; Gahlaut, N.; Suter, R.; Kondo, N.; Melikyan, G.B. Fusion of Mature HIV-1 Particles Leads to Complete Release of a Gag-GFP-Based Content Marker and Raises the Intraviral pH. PLoS ONE 2013, 8, e71002.
133. Ido, E.; Han, H.P.; Kezdy, F.J.; Tang, J. Kinetic-Studies of Human-Immunodeficiency-Virus Type-1 Protease and Its Active-Site Hydrogen-Bond Mutant A28s. J. Biol. Chem. 1991, 266, 24359–24366. [PubMed]
134. Li, Y.F.; Breaker, R.R. Kinetics of RNA degradation by specific base catalysis of transesterification involving the 2’-hydroxyl group. J. Am. Chem. Soc. 1999, 121, 5364–5372. [CrossRef]
135. Hizi, A.; Tal, R.; Shaharabany, M.; Loya, S. Catalytic Properties of the Reverse Transcriptases of Human Immunodeficiency Viruses Type-1 and Type-2. J. Biol. Chem. 1991, 266, 6230–6239. [PubMed]
136. Waheed, A.A.; Tachedjian, G. Why Do We Need New Drug Classes for HIV Treatment and Prevention? Curr. Top. Med. Chem. 2016, 16, 1343–1349. [CrossRef] [PubMed]
137. Sluis-Cremer, N.; Tachedjian, G. Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. Eur. J. Biochem. 2002, 269, 5103–5111. [CrossRef] [PubMed]
138. Andreola, M.L. Therapeutic Potential of Peptide Motifs Against HIV-1 Reverse Transcriptase and Integrase. Curr. Pharm. Des. 2009, 15, 2508–2519. [CrossRef] [PubMed]
139. Restle, T.; Muller, B.; Goody, R.S. Dimerization of Human-Immunodeficiency-Virus Type-1 Reverse-Transcriptase-A Target for Chemotherapeutic Intervention. J. Biol. Chem. 1990, 265, 8986–8988. [PubMed]
140. Agopian, A.; Gros, E.; Aldrian-Herrada, G.; Bosquet, N.; Clayette, P.; Divita, G. A New Generation of Peptide-based Inhibitors Targeting HIV-1 Reverse Transcriptase Conformational Flexibility. J. Biol. Chem. 2009, 284, 254–264. [CrossRef] [PubMed]
141. Wendeler, M.; Lee, H.F.; Bermingham, A.; Miller, J.T.; Chertov, O.; Bona, M.K.; Gotte, M. Vinylogous Ureas as a Novel Class of Inhibitors of Reverse Transcriptase-Associated Ribonuclease H Activity. ACS Chem. Biol. 2008, 3, 635–644. [CrossRef] [PubMed]
142. Chung, S.M.; Wendeler, M.; Rausch, J.W.; Beilhartz, G.; Gotte, M.; O’Keefe, B.R.; Le Grice, S.F. Structure-Activity Analysis of Vinylogous Urea Inhibitors of Human Immunodeficiency Virus-Encoded Ribonuclease H. Antimicrob. Agents Chemother. 2010, 54, 3913–3921. [CrossRef] [PubMed]
143. Chung, S.M.; Miller, J.T.; Johnson, B.C.; Hughes, S.H.; Le Grice, S.F.J. Mutagenesis of Human Immunodeficiency Virus Reverse Transcriptase p51 Subunit Defines Residues Contributing to Vinylogous Urea Inhibition of Ribonuclease H Activity. J. Biol. Chem. 2012, 287, 4066–4075. [CrossRef] [PubMed]
144. Masaoka, T.; Chung, S.; Caboni, P.; Rausch, J.W.; Wilson, J.A.; Taskent-Sezgin, H.; Le Grice, S.F. Exploiting Drug-Resistant Enzymes as Tools To Identify Thienopyrimidinone Inhibitors of Human Immunodeficiency Virus Reverse Transcriptase-Associated Ribonuclease H. J. Med. Chem. 2013, 56, 5436–5445. [CrossRef] [PubMed]